Hodgkin's Disease: The Next Decade

References

• Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., and Peterson, B. A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med., 327, 1478–1484,
   Google Scholar
• Hagemeister, F. (1994) Hodgkin's disease: challenges in diagnosis, staging, and treatment. Diagnostic Oncol., 4, 33–47.
   Google Scholar
• Gospodarowicz, M. K., Sutcliffe, S. B., Bergsagel, D. E., and Chua, T. (1992) Radiation therapy in clinical stage land II Hodgkin's dis-ease. Ear. J. Cancer, 28, 1841–1846.
   Google Scholar
• Carde, P., Hagenbeek, A., Hayat, M., Monconduit, M., Thomas, J., Burgers, M. J. V., Noordijk, E. M., Tanguy, A., Meerwaldt, J. H., Le Fur, R., Somers, R., Kluin-Nelemans, H. C., Busson, A., Breed, W. P., Bron, D., Holdrinet, A., Rutten, E. H. J. M., Michiels, J. J., Regnier, R., Debusscher, L., Musella, R., Fargeot, P., Thyss, A., Cattan, A., Rigal-Huguet, F., Roth, S., Caillou, B., Dupouy, N., and Henry-Amar, M. (1993) Clinical Staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol., 11, 2258–2272.
   Google Scholar
• Fryer, C., Hutchinson, R., Krailo, M., Collins, R., Constine, L., Hays, D.. Heller, R., Davis, P., Nachman, J., O'Brien, R., O'Neill, J., Pringle, K., Trigg, M., and Hammond, G. (1990) Efficacy and tox-icity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a re-port from the Childrens' Cancer Study Group. J. Chn. Oncol., 8, 1971–1980.
   Google Scholar
• Brice, P., Tredaniel, J., Monsuez, J., Marolleau, J., Ferme, C., Hennequin, C., Frija, J., Gisselbrecht, C., and Boiron, M. (1991) Cardiopulmonary toxicity after three courses of ABVD and medi-astinal irradiation in favorable Hodgkin's disease. Ann. Oncol., 2, 73–76.
   PubMed Web of Science ®Google Scholar
• Bates, N. P., Williams, M. V., Bessell, E. M., Vaughan Hudson, G., and Vaughan Hudson, B. (1994) Efficacy and toxicity of vinblas-tine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J. Clin. Oncol., 12, 288–296.
   PubMed Web of Science ®Google Scholar
• Armitage, J. 0. (1994) Early bone marrow transplantation in Hodgkin's disease. Ann. Oncol., 5, 161–163.
   Google Scholar
• Coiffier, B., Philip, T., Burnett, A. K., and Symann, M. L. (1994) Consensus Conference on Intensive Chemotherapy plus Hematopoeitic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6,1993. J. Clin. Oncol., 12, 226–231.
   Web of Science ®Google Scholar
• Klein, G. (1992) Epstin-Barr virus-carrying cells in Hodgkin's dis-ease. Blood, 80, 299–301.
   PubMed Web of Science ®Google Scholar
• Stein, H., Hansmann, M. L., Lennert, K., Brandtzaeg, P., Gatter, K. C., and Mason, D. Y. (1986) Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain. Am. J. Clin. Pathol., 86, 292–297.
   Web of Science ®Google Scholar
• Stein, H., Mason, D. Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., Schwarting, R., and Lennert, K. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplas-tic lymphoid tissue: evidence that Reed-Sternberg cells and histio-cytic malignancies are derived from activated lymphoid cells. Blood, 66, 848–858.
   Google Scholar
• Carbone, A., Gloghini, A, Gattei, V., Aldinucci, D., Degan, M., Canale, V., Zagonel, V., and Pinto, A. (1994) Expression of the CD40 receptor on Reed Sternberg cells (RS): a highly reliable di-agnostic tool and a new clue for understanding the pathophysiology of Hodgkin's disease (HD). Abstract 1261. Proc. Am. Soc. Clin. Oncol., 13,373.
   Google Scholar
• MacLennan, K. A., Bennett, M. H., Tu, A., Vaughan Hudson, B., Easterling, J., Vaughan Hudson, G., and Jelliffe, A. M. (1989) Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer, 64, 1686–1693.
   PubMed Web of Science ®Google Scholar
• Fenry, J., Linggood, R., Convery, K., Efird, J., Eliseo, R., and Harris, N. (1993) Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer, 71,457–463.
   PubMed Web of Science ®Google Scholar
• d'Amore, E. S. G., Lee, C. K. K., Aeppli, D. M., Levitt, S. H., and Frizzera, G. (1992) Lack of prognostic value of histopathologic pa-rameters in Hodgkin's disease, nodular sclerosis type. Arch. Pathol. Lab. Med., 116, 856–861.
   Google Scholar
• Masih, A. S., Weisenburger, D. D., Vose, J. M., Bast, M. A., and Armitage, J. 0. (1992) Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease. Cancer, 69, 228–232.
   Google Scholar
• Hess, J. L., Bodis, S., Pinkus, G., Silver, B., and Mauch, P. (1994) Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer, 74, 708–714.
   PubMed Web of Science ®Google Scholar
• Rodriguez, M. A., Fuller, L. M., Zimmerman, S. 0., Allen, P. K., Brown, B. W., Munsell, M. F., Hagemeister, F. B., McLaughlin, P., Velasquez, W. S., Swan, F., and Cabanillas, F. (1993) Hodgkin's disease: study of treatment intensities and incidences of second ma-lignancies. Ann. Oncol., 4, 125–131.
   Google Scholar
• Valagussa, P., Santoro, A., Fossati-Bellani, F., Banfi, A., and Bonadonna, G. (1986) Second acute leukemia and other malignan-cies following treatment for Hodgkin's disease. J. Chn. Oncol., 4, 830–837.
   PubMed Web of Science ®Google Scholar
• Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., Koch, M., Choi, W., Prior, P., Blair, V., Langmark, F., Pompe Kim, V., Neal, F., Peters, D., Pfeiffer, R., Karjalainen, S., Cuzick, J., Sutcliffe, S. B., Somers, R., Pellae-Cosset, B., Pappagallo, G. L., Fraser, P., Storm, H., and Stovall, M. (1990) Leukemia following Hodgkin's disease. N. Engl. J. Med., 322,7–13.
   Google Scholar
• Pedersen-Bjergaard, J., Specht, L., Larsen, S. 0., Ersboll, J., Struck, J., Hansen, M. M., Hansen, H. H., and Nissen, N. I. (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkin's dis-ease: relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet, 2, 83–88.
   Google Scholar
• Cimino, G., Papa, G., Tura, S., Mazza, P., Rossi Ferrini, P. L., Bosi, A., Amadori, S., Lo Coco, F., D' Arcangelo, E., Giannarelli, D., and Mandelli, F. (1991) Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J. Clin. Oncol., 9, 432–437.
   Google Scholar
• van Leeuwen, F. E., Chorus, A. M. J., van den Belt-Dusebout, A. W., Hagenbeek, A., Noyon, R., van Kerkhoff, E. H. M., Pinedo, H. M., and Somers, R. (1994) Leukemia risk following Hodgkin's dis-ease: relation to cumulative dose of alkylating agents, treatment with ten iposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Oncol., 12, 1063–1073.
   Google Scholar
• Givens, S. S., Fuller, L. M., Hagemeister, F. B., and Gehan, E. A. (1990) Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vin-cristine, procarbazine, and prednisone. Cancer, 66, 69–74.
   PubMed Web of Science ®Google Scholar
• Hagemeister, F. B., Fuller, L. M., and Martin, R. G. (1988) Staging laparotomy: Findings and applications to treatment decisions. In Hodgkin's Disease and Non-Hodgkin's Lymphomas in Adults and Children, edited by L. M. Fuller, F. B. Hagemeister, M. P. Sullivan and W. S. Velasquez, pp. 203–229. New York: Raven Press.
   Google Scholar
• Noordijk, E. M., Carde, P., Mandard, A.-M., Mell ink, W. A. M., Monconduit, M., Eghbali, H., Tirelli, U., Thomas, J., Somers, R., Dupouy, N., and Henry- Amar, M. (1994) Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann. OncoL, 5, 107–112.
   Google Scholar
• Yahalom, J., Ryu, J., Straus, D., Gaynor, J., Myers, J., Caravelli, J., Clarkson, B., and Fuks, Z. (1991) Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's dis-ease treated with alternating chemotherapy combinations. J. Clin. Oncol., 9,2193–2201.
   Web of Science ®Google Scholar
• Fabian, C. .1., Mansfield, C. M., Dahlberg, S., Jones, S. E., Miller, T. P., Slyck, E. V., Grozea, P. N., Morrison, F. S., Coltman, C. A., and Fisher, R. I. (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. Ann. Intern. Med.,120, 902–912.
   Google Scholar
• Doria, R., Holford, T., Prosnitz, L. R., Farber, L. R., and Cooper, D. L. (1994) Second solid tumors (SST) in patients with Hodgkin's disease (HD) after combined modality therapy (CMT). Abstract 1246. Proc. Am. Soc. Clin. OncoL, 13, 369.
   Google Scholar
• Bonfante, V., Santoro, A., Viviani, S., Devizzi, L., Zanini, M., Soncini, F., Gasparini, M., Valagussa, P., and Bonadonna, G. (1994) ABVD plus radiotherapy (subtotal nodal vs. involved field) in early-stage Hodgkin's disease (HD). Abstract 1262. Proc. Am. Soc. Clin. Oncol., 13, 373.
   Google Scholar
• Longo, D. L., Russo, A., Duffey, P. L., Hubbard, S. M., Glatstein, E., Hill, J. B., Jaffe, E. S., Young, R. C., and DeVita, V. T. (1991) Treatment of advanced stage massive mecliastinal Hodgkin's dis-ease: the case for combined modality treatment. J. Clin. Oncol., 9, 227–235.
   PubMed Web of Science ®Google Scholar
• Biti, G. P., Cimino, G., Cartoni, C., Magrini, S. M., Anselmo, A. P., Enrici, R. M., Bellesi, G. P., Boxi, A., Papa, G., Giannarelli, D., Ponticelli, P., Papi, M. G., Rossi Ferrini, P. L., Biagini, C., and Mandelli, F. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective ran-domized study. J. Clin. OncoL, 10, 378–383.
   Google Scholar
• Hagemeister, F. B., Fuller, L. M., Velasquez, W. S., McLaughlin, P., and Cabanillas, F. (1987) Two cycles of MOPP as adjuvant ther-apy for stage I-II Hodgkin's disease. In Adjuvant Therapy of Cancer V. edited by S. E. Salmon, pp. 773–781. Orlando, FL: Grune & Stratton.
   Google Scholar
• Hagemeister, F. B., Cabanillas, F., Velasquez, W. S., Meistrich, M. L., Liang, J. C., McLaughlin, P., Redman, J. R., Romaguera, J. E., Rodriguez, M. A., Swan, F., and Fuller, L. M. (1990) NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin. Oncol., 17, 34–40.
   Google Scholar
• Hagemeister, F. B., Fuller, L., McLaughlin, P., Rodriguez, M., Romaguera, J., Swan, F., and Cabanillas, F. (1992) NOVP and ra-diotherapy for early-staged Hodgkin's disease: an interim analysis. Ann. OncoL, 3, 87–90.
   PubMedGoogle Scholar
• Laremore, D. M., Hagemeister, F. B., and Vassilopoulou-Sellin, R. (1994) Ovarian function and fertility after chemotherapy (Novantrone, Oncovin, vinblastine and prednisone-NOVP) and ra-diotherapy (RI) for Hodgkin's disease. Abstract B-EN-0018. In Proceedings of the Southern Section Meeting, Southern Society for Clinical Investigation (New Orleans, LA, 1994).
   Google Scholar
• Liang, J., Bailey, N., Gabriel, G., Kattan, M., Wang, R., Hagemeister, F. B., Cabanillas, F., and Fuller, L. (1993) A new chemotherapy regimen for treatment of Hodgkin's disease associ-ated with minimal genotoxicity. Leukemia and Lymphoma, 9, 503–508.
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M. A., Cabanillas, F., Lee, J. J., Swan, F., Fuller, L. M., Allen, P. K., and Hagemeister, F. B. (1993) Prognostic role of serum 132-microglobulin in Hodgkin's disease. J. Clin. Oncol., 11, 1108–1111.
   Web of Science ®Google Scholar
• Horning, S. J., Hoppe, R. T., and Hancock, S. L. (1991) Vinblastine, bleomycin and methotrexate: an effective adjuvant in favorable Hodgkin's disease. N. EngL .1. Med., 6, 1822–1832.
   Google Scholar
• Shulman, L. N., Neuberg, D., Gollob, J., and Canellos, G. P. (1994) Etoposide, vinblastine, and doxorubicin (EVA) as initial chemother-apy for patients with advanced Hodgkin's disease. Abstract 1247. Proc. Am. Soc. Clin. OncoL, 13, 369.
   Google Scholar
• Brizel, D. M., Gockerman, J. P., Crawford, J., Hathorn, J. W., Moore, J. 0., Osborne, B., and Prosnitz, L. R. (1994) A pilot study of etopo-side, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. Cancer, 74, 159–163.
   Google Scholar
• Rosenberg, S. A. (1994) The treatment of Hodgkin's disease. Ann. OncoL, 5, 17–21.
   PubMedGoogle Scholar
• Kornblith, A. B., Anderson, J., Cella, D. F., Tross, S., Zuckerman, E., Cherin, E., Henderson, E., Weiss, R. B., Cooper, M. R., Silver, R. T., Lenoe, L., Canellos, G. P., Gottlieb, A., and Holland, J. C. (1992) Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. Cancer, 70, 2214–2224.
   PubMed Web of Science ®Google Scholar
• Kornblith, A. B., Anderson, J., Cella, D. F., Tross, S., Zuckerman, E., Cherin, E., Henderson, E. S., Canellos, G. P., Kosty, M. P., Cooper, M. R., Weiss, R. B., Gottlieb, A., and Holland, J. C. (1992) Comparison of psychosocial adaptation and sexual function of sur-vivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer, 70,2508–2516.
   PubMed Web of Science ®Google Scholar
• Bierman, P., Bagin, R. G., Jagannath, S., Vose, J. M., Spitzer, G., Kessinger, A., Dicke, K. A., and Armitage, J. 0. (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann. Oncol., 4,767–773.
   Google Scholar
• Carella, A. M., Carlier, P., Congiu, A., Occhini, D., Nati, S., Santini, G., Pierluigi, D., Giordano, D., Bacigalup, A., and Damasio, E. (1991) Autologous bone marrow transplantation as adjuvant treat-ment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant., 8, 99–103.
   PubMed Web of Science ®Google Scholar
• Chopra, R., McMillan, A. K., Linch, D. C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K. G., and Goldstone, A. H. (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood, 81, 1137–1145.
   PubMed Web of Science ®Google Scholar
• Gribben, J. G., Linch, D. C., Singer, C. R. J., McMillan, A. K., Jarrett, M., and Goldstone, A. H. (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and au-tologous bone marrow transplantation. Blood, 73, 340–344.
   PubMed Web of Science ®Google Scholar
• Jagannath, S., Armitage, J. 0., Dicke, K. A., Tucker, S. L., Velasquez, W. S., Smith, K., Vaughan, W. P., Kessinger, A., Horwitz, L. J., Hagemeister, F. B., McLaughlin, P., Cabanillas, F., and Spitzer, G. (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's dis-ease. J. Clin. OncoL, 7, 179–185.
   Google Scholar
• Becker, T. A., Greer, J. P., Stein, R. S., Brandt, S. J., Goodman, S. A., Shahab, I., Cousar, J. B., and Wolff, S. N. (1994)Presenting fea-tures and factors affecting outcome in patients undergoing bone mar-row transplantation (BMT) for relapsed Hodgkin's disease (HD). Abstract 1253. Proc. Am. Soc. Clin. Oncol., 13,371.
   Google Scholar
• Lowsky, R., Lipton, J., Fyles, G., Minden, M., Meharchand, J., Tejpar, I., Atkins, H., Sutcliffe, S., and Messner, H. (1994) Secondary malignancies after bone marrow transplantation in adults. J. Clin. Oncol., 12, 2187–2192.
   Web of Science ®Google Scholar
• Brandwein, J. M., J, C., Sutcliffe, S. B., Scott, J. G., and Keating, A. (1990) Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant., 5, 99–103.
   PubMed Web of Science ®Google Scholar
• Rapoport, A. P., Rowe, J. M., Kouides, P. A., Duerst, R. A., Abboud, C. N., Liesveld, J. L., Packman, C. H., Eberly, S., Sherman, M., Tanner, M. A., Constine, L. S., and DiPersio, J. F. (1993) One hun-dred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J. Clin. OncoL, 11, 2351–2361.
   Google Scholar
• Smith, M. R., Khanuja, P. S., Al-Katib, A., Bishop, C. R., Andersen, J., Hussein, M. E., and Karanes, C. (1994) Continuous infucion ABDIC therapy for relapsed or refractory Hodgkin's disease. Cancer, 73, 1264–1269.
   Google Scholar
• Straus, D. J., Passe, S., Koziner, B., Lee, B. J., Young, C. W., and Clarkson, B. D. (1981) Combination chemotherapy salvage of heav-ily pretreated patients with Hodgkin's disease: an analysis of prog-nostic factors in two chemotherapy trials and the literature. Cancer Treat Rep 65: 207–211.
   PubMedGoogle Scholar
• Proctor, S. J., Taylor, P., Donnan, P., Boys, R.. Lennard, A., and Prescott, R. J. (1991) A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at di-agnosis. Eur. J. Cancer, 27,624–629.
   Web of Science ®Google Scholar
• Gianni, A. M., Siena, S., Bregni, M., Lombardi, F., Gandola, L., Valagussa, P., and Bonadonna, G. (1991) Prolonged disease-free survival after high-dose sequential chemoradiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann. Oncol., 2,645–653.
   PubMed Web of Science ®Google Scholar
• Somers, R., Carde, P., Henry-Amar, M., Tarayre, M., Thomas, J., Hagenbeek, A., Monconduit, M., de Pauw, B. E., Breed, W. P. M., Verdonck, L., Burgers, J. M. V., Eghbali, H., and Zittoun, R. (1994) A randomized study in stage IIIB and IV Hodgkin's disease com-paring eight courses of MOPP versus an alternation of MOPP with ABVD. J. Clin. Oncol., 12, 279–287.
   Google Scholar
• Brusamolino, E., Orlandi, E., Mona, E., Castelli, G., Pagnucco, G., Livraghi, A., Astori, C., Santagostino, A., Lazzarino, M., and Bernasconi, C. (1994) Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Ann. Oncol., 5, 53–57.
   PubMedGoogle Scholar
• Körbling, M., Holle, R., Haas, R., Knauf, W., Dörken, B., Ho, A. D., Kuse, R., Pralle, H., Fliedner, T. M., and Hunstein, W. (1990) Autologous blood stem-cell transplantation in patients with ad-vanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol., 8, 978–985.
   Google Scholar
• Haas, R., Hohaus, S., Egerer, G., Ogniben, E., Witt, B., and Hunstein, W. (1994) Peripheral blood stem cell transplantation in malignant lymphomas. Intl. J. Cell Cloning, 10, 138–140.
   Google Scholar
• Kessinger, A., Vose, J., Bierman, P., Bishop, M., and Armitage, J. (1994) Peripheral blood stem cell transplantation in malignant lym-phomas. Hem/Onc Ann., 2,45–52.
   Google Scholar
• Bartlett, N. L., Rosenberg, S. A., Hoppe, R. T., and Horning, S. J. (1993) A brief dose-intense chemotherapy regimen, Stanford V, is highly effective for unfavorable Hodgkin's disease (HD). Abstract 1262. Proc. Am. Soc. Clin. Oncol., 12, 372.
   Google Scholar
• Bonadonna, G. (1994) Modem treatment of malignant of malignant lymphomas: a multidisciplinary approach? Ann. Oncol., 5, 5–16.
   Google Scholar